Vericel Co. (NASDAQ:VCEL) Insider Sells $67,693.08 in Stock

Vericel Co. (NASDAQ:VCEL) insider Jonathan Siegal sold 1,092 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total transaction of $67,693.08. Following the transaction, the insider now owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. This represents a 47.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Jonathan Siegal also recently made the following trade(s):

• On Tuesday, January 28th, Jonathan Siegal sold 3,908 shares of Vericel stock. The shares were sold at an average price of $61.99, for a total transaction of $242,256.92.

Vericel Stock Down 2.3 %

Shares of VCEL stock opened at $58.35 on Friday. The firm has a market cap of $2.88 billion, a PE ratio of 972.66 and a beta of 1.72. Vericel Co. has a 12 month low of $39.12 and a 12 month high of $63.00. The company’s fifty day simple moving average is $57.84 and its 200-day simple moving average is $51.11.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. On average, equities analysts predict that Vericel Co. will post 0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on VCEL shares. Canaccord Genuity Group lifted their target price on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research report on Tuesday, December 24th. Stephens restated an “overweight” rating and set a $65.00 target price on shares of Vericel in a report on Wednesday, January 15th. BTIG Research upped their price target on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Vericel in a report on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Vericel currently has an average rating of “Moderate Buy” and an average target price of $63.14.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VCEL. FMR LLC increased its position in shares of Vericel by 1.0% during the 3rd quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company’s stock worth $100,251,000 after purchasing an additional 22,461 shares during the last quarter. Conestoga Capital Advisors LLC raised its position in Vericel by 1.7% during the third quarter. Conestoga Capital Advisors LLC now owns 2,075,730 shares of the biotechnology company’s stock worth $87,700,000 after acquiring an additional 34,360 shares in the last quarter. Congress Asset Management Co. lifted its stake in Vericel by 12.6% in the fourth quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company’s stock valued at $79,847,000 after acquiring an additional 162,419 shares during the last quarter. GW&K Investment Management LLC grew its position in shares of Vericel by 2.4% in the 4th quarter. GW&K Investment Management LLC now owns 1,273,964 shares of the biotechnology company’s stock valued at $69,953,000 after acquiring an additional 30,180 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Vericel by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock valued at $48,768,000 after acquiring an additional 9,613 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.